William Blair analyst Matt Larew has maintained their bullish stance on WST stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Buy rating due to a combination of factors including West Pharmaceutical Services’ strong third-quarter performance, which exceeded both the firm’s and market expectations. The company’s revenue reached $804.6 million, surpassing the estimated $789.3 million, driven by a 5.0% organic growth. Proprietary products and high-value product (HVP) components significantly contributed to this growth, with HVP components making up 48% of total sales.
Additionally, the company has raised its guidance for 2025, projecting increased sales and earnings per share, which indicates confidence in its future performance. The guidance now forecasts reported sales between $3.060 billion and $3.070 billion, with organic growth expected to be between 3.75% and 4%. This positive outlook, coupled with the easing of inventory destocking and growth in key product areas like GLP-1s, supports the Buy rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $318.00 price target.